Objectives: To determine the extent that zoledronate (ZOL) dose and duration is associated with bisphosphonate-related osteonecrosis of the jaw (BRONJ) prevalence in rice rats with generalized periodontitis (PD), characterize structural and tissuelevel features of BRONJ-like lesions in this model, and examine the specific anti-resorptive role of ZOL in BRONJ. 
| INTRODUC TI ON
Medication-related osteonecrosis of the jaw (MRONJ) is a potentially severe adverse event characterized by persistent exposure of necrotic bone in the jaw (Ruggiero et al., 2014) in patients treated with potent anti-resorptives (pARs) [e.g., nitrogen-containing bisphosphonates, N-BPs (Marx, 2003; Ruggiero et al., 2014) , and receptor activator of NFκB ligand antibodies (Stopeck et al., 2010; Van den Wyngaert, Wouters, Huizing, & Vermorken, 2011) ]. More recently, MRONJ has been observed in patients with cancer taking anti-angiogenic medication (e.g., vascular endothelial growth factor antibodies) (Carlson & Schlott, 2014; Eleutherakis-Papaiakovou & Bamias, 2017; Fusco, Santini, Armento, Tonini, & Campisi, 2016; Khan et al., 2017; Ramirez, Lopez-Pintor, Casanas, Arriba, & Hernandez, 2015; Voss, Poxleitner, Schmelzeisen, Stricker, & Semper-Hogg, 2017 ). In ONJ cases in which the only systemically administered medication is an N-BP, the term bisphosphonate-related osteonecrosis of the jaw (BRONJ) may also be used.
Systemic administration of these medications is specified in the clinical definition of MRONJ as a requirement for a formal diagnosis (Ruggiero et al., 2014) . However, local factors in the oral cavity, despite being absent from the formal definition of MRONJ, also increase risk and play a crucial role in the disease process (Aghaloo, Hazboun, & Tetradis, 2015; Aljohani et al., 2017; Carlson & Schlott, 2014; Eleutherakis-Papaiakovou & Bamias, 2017; Filleul, Crompot, & Saussez, 2010; Hamadeh, Ngwa, & Gong, 2015; Khan et al., 2017; Marx, 2003; Otto et al., 2012; Voss et al., 2017; Yoneda et al., 2017) .
Discrete oral procedures involving the dentoalveolar bone (e.g., tooth extraction) are considered the most common local oral factor associated with MRONJ and are estimated to occur in 52%-86% of MRONJ cases (Aghaloo et al., 2015; Aljohani et al., 2017; Carlson & Schlott, 2014; Eleutherakis-Papaiakovou & Bamias, 2017; Filleul et al., 2010; Hamadeh et al., 2015; Khan et al., 2017; Marx, 2003; Otto et al., 2012; Ruggiero et al., 2014; Voss et al., 2017; Yoneda et al., 2017) . Delaying the start of risk factor medications until surgical sites have healed, and ensuring appropriate perioperative management, including antibiotic coverage, are often effective means to prevent MRONJ associated with dentoalveolar surgery (Dimopoulos et al., 2009; Hoefert & Eufinger, 2011; Montefusco et al., 2008; Ripamonti et al., 2009; Vandone et al., 2012) . However, periodontitis (PD) and periapical infection Li et al., 2016; Song et al., 2016) have also been identified as important risk factors for BRONJ/MRONJ in patients without recent dentoalveolar surgery (Carlson & Schlott, 2014; EleutherakisPapaiakovou & Bamias, 2017; Khan et al., 2017; Marx, 2003; Voss et al., 2017) . While oral diseases involving the periodontal tissues appear to contribute to MRONJ directly, they may also contribute to cases related to dentoalveolar surgery, since teeth that require extraction often have some degree of acute or chronic infection (e.g., infection from caries, periodontal disease). Cases in which MRONJ arises without a recent dentoalveolar surgery may be more difficult to anticipate and treat, especially if these conditions are not fully resolved before beginning pAR treatment, or if they arise after pAR treatment has started. Therefore, studies that investigate the role of specific oral inflammatory diseases as local oral risk factors for MRONJ are important to develop a comprehensive understanding of the pathophysiology of the disease, and contribute evidence that might be used to develop preventative or therapeutic strategies.
Rice rats (Oryzomys palustris) develop two distinctive types of PD that require no surgical or local mechanical intervention: (a) a generalized form, which affects both maxillae and mandibles, and is accelerated by a high sucrose-casein diet (HSC) (Aguirre, Akhter, Kimmel, Pingel, Xia et al., 2012; Aguirre et al., 2016; Gotcher & Jee, 1981; ; and (b) a localized form (food impaction localized PD, FILP), which overwhelmingly affects the maxillary interdental space between molar (M) 2 and M3 and is found in rice rats fed standard rodent chow (STD) (Messer et al., 2017) . Importantly, rice rats fed HSC diet do not develop FILP lesions. Therefore, two different PD models can be generated in rice rats by dietary modification alone.
The pelleted HSC diet that accelerates generalized PD is based on the powdered Harvard high sucrose 700 and the ration 100 diets used in previous studies to accelerate the onset of PD in rice rats (Auskaps, Gupta, & Shaw, 1957; Gotcher & Jee, 1981; Ryder, 1980) . The reason the pelleted HSC diet does not produce FILP Aguirre, Akhter, Kimmel, Pingel, Xia et al., 2012) is possibly due to the low content (3%) of insoluble fibre provided as powdered cellulose, which is in contrast to STD rodent chow (irradiated diet no. 7912, Teklad LM-485 Rodent Diet; Envigo, Tampa, FL), which contains 13.7% neutral detergent fibre (NDF) and 4.6% of crude fibre. These fibrous components of the STD chow diet appear to contribute to the initiation and persistence of FILP lesions.
The defining feature of the FILP model is direct injury to soft tissue in the maxillary interdental M2-M3 space by persistent presence of impacted plant fibre and cellular debris. Food impaction around teeth, dental implants, or embrasures in humans may also result in peri-implantitis or peri-coronitis (Du, Gao, Qi, Liu, & Lin, 2010) , and is an important risk factor for localized PD in humans (Matthews & Tabesh, 2004; Nunn, 2003) . Conversely, clinical and histopathologic examination of generalized PD in the rice rat shows marked accumulation of microbial plaque on molar surfaces and inflammation of periodontal tissues. This type appears to resemble human PD, in which biofilms are an important mediator and contributing factor to the pathophysiology of the disease (Genco & Borgnakke, 2013; Offenbacher, 1996; Page, Offenbacher, Schroeder, Seymour, & Kornman, 1997; Salvi, Lawrence, Offenbacher, & Beck, 1997) .
Rice rats with either type of PD, and without dentoalveolar surgery, develop BRONJ-like lesions when simultaneously exposed to clinically relevant doses of the systemic pAR, zoledronate (ZOL) Messer et al., 2018) . Importantly, the anatomical distribution of BRONJ-like lesions appears to be associated with the anatomical location of the PD in individual rats. Specifically, rice rats fed STD diet and injected with ZOL developed BRONJ-like lesions primarily at the same location as the FILP lesions, the M2M3 maxillary interdental space (Messer et al., 2018) , whereas rats fed HSC diet and injected with oncologic ZOL developed BRONJ-like lesions equally in the four jaw quadrants .
These findings suggest that rats given clinically relevant doses of ZOL are more likely to develop BRONJ-like lesions in quadrants that are also directly affected by oral inflammation.
In humans, various local oral risk factors (e.g., oral infections, surgical/trauma events and inflammatory disease), when combined with systemic risk factor medications, can result in MRONJ. However, it is not clear if different local oral risk factors result in distinctive patterns in the relationship between MRONJ prevalence and dose and duration of systemic risk factor medications. The rice rat provides a unique opportunity to explore this hypothesis given the distinctive types of PD that exist in this species. Previous findings demonstrated that BRONJ-like lesions occur in rice rats with localized PD (FILP) in a positive dose-dependent manner, but ZOL duration did not have a significant effect on the prevalence of BRONJ-like lesions, which plateaued between 18 and 30 weeks of treatment (Messer et al., 2018) . Importantly, 50%-75% of vehicle-treated STD diet rats show FILP-induced mucosal injury by age 16 weeks. This finding is in direct contrast to the age-related progression of generalized PD which does not become moderate to severe in a majority of rats until later, at age 22 weeks (Aguirre, Akhter, Kimmel, Pingel, Xia et al., 2012) . These findings suggest that the effect of ZOL dose and duration on BRONJ-like lesion prevalence in rice rats with generalized PD could differ from that in rice rats with localized PD. Examining how different oral risk factors work alongside systemic medications may provide important data that improves the current understanding of how different periodontal risk factors interact with systemic medications to initiate MRONJ.
The primary purposes of this study were to: (a) define the relationship between ZOL dose and duration and prevalence of BRONJlike lesions in rice rats with generalized PD, (b) characterize the overall structure and tissue-level features of alveolar bone in ZOLtreated rice rats with and without BRONJ-like lesions by MicroCT and histologic techniques and (c) examine the association between the anti-resorptive effect of ZOL at clinically relevant doses and the presence of BRONJ-like lesions.
We hypothesize that: (a) increased dose and duration of ZOL will increase the prevalence of BRONJ-like lesions in rice rats with generalized PD in a pattern that is distinctive from previous findings in rats with localized PD; (b) ZOL and BRONJ-like lesions will alter the structure and tissue-level features of the jaw; and (c) ZOL dose will be associated with reduced osteoclast number in the jaw and suppressed systemic bone resorption. Testing the first hypothesis will involve using data from a previously reported experiment (Messer et al., 2018) conducted simultaneously to this one.
| MATERIAL S AND ME THODS

| Animal care
A monogamous continuous-breeding system was used to generate the experimental rice rats. All rats were housed (2-5 per cage) in static filter top cages (area: 143 in 2 ) with pine shavings and continuous access to food and water. The housing rooms were maintained at 20-26ºC with humidity of 30%-70% and a 12:12 hr light:dark cycle, or 14:10 hr cycle for breeders (Aguirre et al., 2015) . Experimental animals ate pelleted, semi-purified HSC diet (TestDiet 5SXA AIN-93G w/no Complex Carbohydrates; Smelt Feed and Pet Supply, Tampa, FL, USA), which can be fed for up to 30 weeks without inducing significant metabolic abnormalities (Aguirre et al., 2016) . This diet is based on the formula of the powdered Harvard high sucrose 700 diet and the ration 100 diet previously used to accelerate generalized PD in rice rats (Auskaps et al., 1957; Gotcher & Jee, 1981; Ryder, 1980 A previous study showed that both male and female rice rats given oncologic doses of ZOL develop BRONJ . Only females were used in the current study to avoid variation in measurements due to sexual dimorphism (Aguirre et al., 2015) . All groups were fed pelleted HSC diet and received intravenous (IV) injections of 0 (n = 42), 8 (n = 44), 20 (n = 44), 50 (n = 40), or 125 µg/kg BW of ZOL (n = 46) every four weeks (q4wk), starting at 4 weeks of age. After 12, 18, 24 and 30 weeks of treatment, duration subgroups (n = 9-16) from each of the five dose groups were necropsied (Supporting Information Table S1 and Figure   S1 ). The minimum sample size (n = 9) was determined by power calculation (see Statistical Analysis, Section 2.11). Animals were added to later time points based on a 10% censor rate to account for rats removed from the study before reaching scheduled time points, based on attrition rates from previous long-term rice rat studies.
To compose each duration subgroup, rats with progressive BW loss that reached ≥15% were chosen to comply with humane endpoints specified in the IACUC protocol. The remaining rats for each duration subgroup were selected by BW randomization. No more than 30% of each dose/duration subgroup was composed of rats that met the BW loss endpoint criteria for euthanasia.
| ZOL dose
The dosing strategy has been previously described (Messer et al., 2018 
| Euthanasia and tissue collection
Rats were euthanized by CO 2 followed by cardiac puncture to withdraw about 1.5 ml of whole blood. Cervical dislocation was used as a secondary confirmatory method of euthanasia. Maxillae and mandibles were excised as before (Messer et al., 2018) . High-resolution (HR) photographs from the medial aspect of each hemi-mandible (Supporting Information Figure S2a ) and ventral aspect of each hemi-maxillae (Supporting Information Figure S2b ) were taken with a digital camera (Canon EOS 6D; Tokyo, Japan) attached to a macro lens (Canon EF 100 mm 1:2.8; Tokyo, Japan). Jaw quadrants were fixed at 4°C in freshly prepared 4% paraformaldehyde, then transferred to 70% ethanol after 48 hr.
| Gross analysis of oral lesions
Jaw quadrant photographs were independently assessed by blinded observers (JGM, DBK, JIA). Quadrants were assigned a Gross Quadrant Grade (GQG) that reflected the severity of its gross lesions (Table 1 ) (Messer et al., 2018) . Photographs of representative maxillae and mandibles representing each GQG are shown in Supporting Information Figure S2 . When at least one quadrant in a rat had an area of exposed bone, the rat was considered positive for a gross BRONJ-like lesion. Neither pocket depth nor clinical attachment level by probing were evaluated. Photographs that did not receive the same GQG from all three independent observers were re-examined by all three observers together, and a GQG was assigned when consensus was reached. and ulceration. For rats with BW loss, all quadrants were analysed because data from a previous study showed that rice rats with BRONJ-like lesions had BW loss compared to rice rats without these lesions (Messer et al., 2018 ). In the current study, 37% (80/218) of rats necropsied at weeks 12-30 exhibited BW loss. 92% of rats with gross BRONJ-like lesions (22/24) and 73% (22/30) of rats with BRONJ-like lesions diagnosed only using histopathology (without prior gross diagnosis) had BW loss.
| Specimen selection for PD analysis
Right maxillae and mandibles from all ZOL 0 rats, and right maxillae from baseline rats, regardless of GQG, were examined to determine periodontal status and assigned a PD Score (Table 2) . When right quadrants were not available, left quadrants were used.
| Histological preparation of jaw quadrants
Maxillae and mandibles selected for sectioning were decalcified in 5% formic acid under gentle agitation for 4 weeks, with three changes per wk. Decalcified jaw quadrants were trimmed, paraffin-embedded, and sectioned at 5 µm thickness in the mesiodistal plane from the lingual to buccal aspect of each quadrant (Leica/ Jung 2265 and Accu-Cut SRM 200 Sakura microtomes, Sakura
Finetek Europe B.V, Zoeterwoude, The Netherlands). Maxillae and mandibles were serially sectioned at five or six levels, starting approximately 1 mm lateral to the midline of the palate or at the lingual plate, respectively. Levels were separated by approximately 250 µm, allowing thorough examination of tissues at the lingual surface (one or two levels), around the molars (three levels), and at the buccal surface (one level). Sections were H&E stained and cover slipped.
| Histopathologic definition of BRONJ-like lesions and quantification of necrotic bone
Histopathologic BRONJ-like lesions were defined as bone that was both exposed and necrotic in at least one level within a quadrant.
Exposed bone was identified by a lack of overlying gingival epithelium, lamina propria, and periodontal ligament (PDL). Necrotic bone was identified using (a) a pattern recognition approach as previously described (Franco-Pretto, Pacheco, Moreno, Messa, & Gnecco, 2014; Hellstein, 2014; Yang et al., 2009; Zheng et al., 2018), and (b) by specific criteria used in previous preclinical studies of BRONJ that define necrotic bone as bone matrix containing ≥10 adjacent lacunae that were empty, or had pyknotic osteocyte nuclei or cellular debris (Kuroshima & Yamashita, 2013; Yamashita, Koi, Yang, & McCauley, 2011) . All levels were surveyed independently by two observers (JGM and JIA). When diagnoses differed, agreement was reached after reviewing slides together. A rat with at least one quadrant that met the definition above was considered positive for BRONJ.
To quantify bone necrosis, the number of lacunae that were empty or contained pyknotic nuclei was counted. 
| Histopathologic characterization of PD
Sections were assessed for PD Score (Table 2 ) and alveolar bone loss as previously described (Aguirre, Akhter, Kimmel, Pingel, Xia et al., 2012) . A quadrant with PD Score ≥1 was considered positive for PD.
A rat with at least one quadrant with PD Score ≥1 was considered positive for PD. The rat PD Score is the highest quadrant PD score for that animal. Alveolar bone height (ABH) was assessed in both maxillae and mandibles by measuring the distance between the cementoenamel junction (CEJ) and the crest of the alveolar bone, as previously described (Figure 2d ) Aguirre et al., 2016) . Measurements were made in one section from the lingual aspect of the M1M2 interdental space. A larger ABH value indicates greater loss of alveolar bone.
Measurements were made in blinded, randomized order (JGM). ABH in baseline rats was only measured in maxillae.
| Osteoclast quantification
To assess the local effect of ZOL, PD, and BRONJ on osteoclasts in the jaws, osteoclasts were analysed on the surfaces of maxillary alveolar bone with PD (PD Score ≥1) in rats treated with ZOL 0 (n = 11) or (Bouxsein et al., 2010) . Images were acquired using the following parameters: 80 kVP/120 µA, 0.5 mm aluminium filter, 2k camera resolution, 10 µm voxel size, 0.5° rotation step, and 360° tomographic rotation.
| MicroCT
Two analyses were completed. First, 2D images were aligned in the mesiodistal plane with all molars simultaneously visible for qualitative image analysis. Second, 2D images from the mesial aspect of M2 were aligned in the buccolingual plane and the width of the alveolar ridge was measured (Figure 9d ). Mandibles from ZOL 0 rats were compared to rats treated with oncologic ZOL (20-125). To consistently measure the same area in all mandibles, the slice through the apical foramen of the mesial root of M2 was selected. Then, the vertical length of M2 between the CEJ and apex of the mesial root was measured. The buccolingual width of the alveolar ridge was then measured perpendicular to the M2 mesial root at 30% (coronal width) and 60% (apical width) the total length of the CEJ-apex distance (ImageJ Software, NIH). After scanning, quadrants underwent histopathologic analysis (See Sections 2.6 and 2.7). and cortical bone at the mid-diaphysis), as previously described (Ke, Qi, Chidsey-Frink, Crawford, & Thompson, 2001 ).
| Peripheral quantitative computed tomography
| Serum ELISA
Serum concentration of P1NP, a bone formation marker and tartrateresistant acid phosphatase 5b (TRAcP 5b), a marker of osteoclast number, were measured to characterize the systemic effects of ZOL on the skeleton. After cardiac puncture, blood was allowed to clot at room temperature and centrifuged, and serum was collected and stored at −20°C. Rat/Mouse P1NP EIA and the MouseTRAP kits were used, per manufacturer's instructions (Immunodiagnostic Systems;
Tyne & Wear, UK), in serum collected from rats treated for 24 weeks.
| Statistical analysis
Chi-square test was used to determine the relationship between BW loss and occurrence of BRONJ, between PD type (localized or generalized) and oral lesion location (maxilla or mandible), and between PD type (localized or generalized) and total number of BRONJ cases. Multiple logistic regression analysis was used to determine whether dose and duration were significant predictors of BRONJ prevalence among individual dose levels, and when the doses were stratified in three groups: control (ZOL 0), OP (ZOL 8) and oncology doses (ZOL 20, 50, 125) . Data are expressed as Mean ± SD. For ABH, osteocyte lacunae, and ELISA, one-way ANOVA with HolmSidak post hoc analysis was used to assess intergroup differences.
When assumptions of data normality were not met, a Kruskal-Wallis ANOVA on Ranks followed by Dunn's multiple comparison was applied. Spearman rank correlation was used to determine whether PD Score increased with age. Student's t test was used to determine differences in the alveolar ridge width measurements between ZOL 0 and ZOL-treated rats. Two-way ANOVA was used to assess the main effects of ZOL dose and duration on pQCT measurements. Twoway ANOVA was also used to determine the main effects of oral health status (healthy, PD, BRONJ) and ZOL dose on TRAP+/B.Pm.
The means of the ZOL dose groups were collapsed into a single PD group for comparison with BRONJ using Student's t test. A power calculation was performed using SAS PROC POWER logistic regression. This experiment has 80% power to determine significant differences in BRONJ prevalence between control and 125 µg/kg BW ZOL. In all cases, p < 0.05 was considered statistically significant.
| RE SULTS
| Periodontitis status (ZOL 0 rats)
All quadrants in baseline rats had GQG 0 with PD Score 0 ± 0. PD was prevalent in 60, 56, 80 and 92% of ZOL 0 rats at 12, 18, 24 and 30 weeks, respectively (Figure 2a ). In rats with PD, PD Score ranged from 1-4, and there was a significant positive correlation between PD Score and duration on HSC diet (R = 0.496, p = 0.00124) (Figure 2b ).
There was significantly greater alveolar bone loss at 24 and 30 weeks than at 12 and 18 weeks in mandibles, and at 12, 24 and 30 weeks than at baseline in maxillae (Figure 2c ). Moderate PD in rice rats (PD Score 3) rats showed bacterial plaque, apical migration of junctional epithelium, alveolar bone resorption, increased ABH, gingival hyperplasia, inflammatory infiltrate, and PDL disruption (Figure 2d ).
| Prevalence of BRONJ-like lesions
The prevalence of gross BRONJ-like lesions is shown (Figure 3a (45/130 rats), respectively. Both ZOL dose (p < 0.001) and duration (p < 0.001) were significant predictors of histopathologic BRONJ prevalence when stratified this way. One maxilla met all criteria for BRONJ in a ZOL 0 rat at age 34 weeks.
| Features of BRONJ lesions
| Gross and histopathologic
Gross BRONJ-like lesions were found in both maxillae ( Figure 4a) and mandibles ( Figure 4d ) and showed exposed bone, ulcerated mucosa, plaque and irregular gingival contours around the margins of the molars. Gross oral lesions were distributed evenly between the maxillae (46%) and mandibles (54%) (p = 0.1953).
Histopathologic BRONJ-like lesions in both maxillae (Figure 4b, c) and mandibles (Figure 4e ,f) were characterized by confluent areas of empty osteocyte lacunae in bone exposed to the oral cavity, and the surface was usually colonized by bacteria. Mucosal and periodontal tissues around the margins of the lesions had marked inflammatory infiltrate. Haemorrhage, fibrosis, numerous reversal lines in bone and necrotic soft tissue were also apparent.
BRONJ-like lesions occurred in different areas of alveolar bone, including interdental regions, the M1 interradicular bone, distal to M3, or on the hard palate or lingual plate. Necrotic bone was observed underneath intact mucosa in some sections. However, in all such cases, exposed necrotic bone was present in sections from adjacent levels within the same quadrant (Supporting Information Figure S3 ).
The percentage of empty osteocyte lacunae in BRONJ rats was significantly higher (p < 0.05) than in PD control rats in the oncologic ZOL dose groups (20-125) (Figure 4g ), and similar results were found when empty osteocyte lacunae frequency was normalized to bone area ( Figure 4h ). 
F I G U R E 3 Prevalence of BRONJ. (a) Prevalence of gross BRONJ (highresolution photographs
| MicroCT
Periodontitis-affected mandibles exhibited loss of ABH mesial to M1, in the M1 furcation, and in the M1M2 interdental region (Figure 5b ), 
| Alveolar bone osteoclasts
Compared to ZOL 0 rats with no PD (Figure 6a 
| D ISCUSS I ON
This study demonstrates that longer duration of oncologic doses of ZOL is associated with a higher prevalence of BRONJ in rice rats that are simultaneously developing generalized PD. BRONJ prevalence appeared to plateau at an oncologic ZOL dose (ZOL 20) that was and time (p < 0.001) were significant for all measurements, and there were some significant differences among doses within each time point. However, there were no significant differences among the ZOL oncology doses at any time. *indicates p < 0.05 compared to 0 ZOL; ‡ indicates p < 0.05 compared to 0 ZOL and 8 ZOL. Mean ± SD PD via dental ligature (Li et al., 2016) and in association with localized intraoral lesions where impacted food and hair produce periodontal inflammation (Messer et al., 2018; de Molon et al., 2014) .
The requirement of local oral factors is also supported in the current study by a subpopulation of rice rats (32%) given oncologic doses of ZOL that never developed BRONJ despite receiving cumulative ZOL doses up to 1,000 µg/kg over 30 weeks. These rats had GQG of 0 (92%) or 1 (8%), and exhibited no BW loss at necropsy, suggesting healthy oral cavities. Similarly, Sprague Dawley rats treated up to 2 years with alendronate at up to 10 times the OP dose and ZOL at up to seven times the oncology dose show no BRONJ-like lesions (Merck, 2018; Novartis, 2018) , possibly because of the known resistance of rodents from the genus Rattus to develop PD (Graves, Kang, Andriankaja, Wada, & Rossa, 2012; Oz & Puleo, 2011; Struillou, Boutigny, Soueidan, & Layrolle, 2010; Weinberg & Bral, 1999) .
While inflammation or infection from oral diseases, or direct compromise of the gingival barrier via a wound, appears to be crucial for developing BRONJ, evidence from rice rat studies suggests that the type of oral inflammation may produce BRONJ in distinctive patterns, and with distinctive features when bone resorption is suppressed by ZOL. In the FILP model, BRONJ-like lesions developed primarily in maxillae (74%) compared to mandibles (26%) (p < 0.0001), and there was a significant increase in prevalence dependent on dose, but not duration of ZOL treatment (Messer et al., 2018 ). In the current study, rice rats fed the HSC diet developed generalized PD but not FILP. In this generalized PD model, BRONJ lesions were distributed evenly between maxillae and mandibles, and were associ- which the time-to-onset of BRONJ after exposure to pARs is widely variable, ranging from 0.1 to 19.9 years (Fung et al., 2017) .
The histopathological examination of BRONJ-like lesions at the tissue level was consistent with previous studies in rice rats, where exposed necrotic bone with attached bacterial colonies was observed (Aguirre, Akhter, Kimmel, Pingel, Xia et al., 2012) . In the current study, osteonecrosis was not found under intact mucosa in any of the 198 examined quadrants. Additionally, four lesions showed bone that was exposed, but vital. Taken together, these novel findings suggest that bone in the periodontal lesion of pAR-treated subjects may become exposed before becoming necrotic. pARs with clinical findings of moderate/advanced PD or periapical pathology, such as bleeding on probing or intermittent tooth sensitivity, may actually have exposed, necrotic bone in periodontal pockets or in the periapical region that is only histologically detectable.
One maxilla met all criteria for a BRONJ-like lesion in a ZOL 0 rat at age 34 weeks, indicating that dead alveolar bone in rice rats with severe PD that were not treated with a pAR, can occasionally accumulate in sufficient quantity to be diagnosed as BRONJ. Bone necrosis is not generally observed in clinical examination of humans with severe PD who do not take pARs. This may be due to lack of routine tissue biopsy of severe PD lesions in humans, or because necrotic bone may be promptly removed by normal osteoclastic activity in the absence of pARs. Indeed, delayed removal of necrotic bone in humans taking pARs has been observed clinically in the treatment of femoral head osteonecrosis (Agarwala & Shah, 2011; Hong, Luo, Lin, Zhong, & Shi, 2014; Lai et al., 2005; Luo, Lin, Zhong, Yan, & Wang, 2014) , suggesting that pARs may also cause persistence of necrotic bone induced by severe PD in the oral cavity, which could eventually result in clinically detectable MRONJ. Alternatively, oral ulceration with bone sequestration (Almazrooa & Woo, 2009; Farah & Savage, 2003; Khan et al., 2015; Palla, Burian, Klecker, Fliefel, & Otto, 2016; Peters, Lovas, & Wysocki, 1993; Sonnier & Horning, 1997 ) occurs in humans not taking pARs and may have some relevance to this finding.
MicroCT images of mandibles affected with BRONJ-like lesions revealed mottling of alveolar bone distant from the necrotic bone tissue region identified histologically. These pores may be the result of osteoclast activity far from localized sites where necrotic bone has accumulated. This finding suggests that the presence of exposed necrotic bone tissue may activate bone resorption throughout the entire alveolar process of the afflicted quadrant, bearing similarity to a regional acceleratory phenomenon (RAP) (Duncan, Frame, Frost, & Arnstein, 1969; Mueller, Schilling, Minne, & Ziegler, 1991; Verna, 2016) . Indeed, the number of TRAP+ osteoclasts per mm bone perimeter was significantly higher in maxillary alveolar bone of BRONJ-affected rats, compared to maxillary alveolar bone of rats affected by PD, suggesting that exposed necrotic bone with a more extensive area of soft tissue damage and inflammation promote a greater recruitment and activation of osteoclasts.
MicroCT analysis also revealed that ZOL monotherapy can increase the width of the alveolar process in rice rats. This provides further evidence that in rats at risk for BRONJ, the entire alveolar was reduced to similar levels by ZOL after 24 weeks of treatment.
Serum TRAcP 5b was not significantly altered by ZOL except at the ZOL 50 dose, which was higher than control (ZOL 0) and other ZOL doses. Together, these findings suggest that BRONJ prevalence may be associated specifically with the well-characterized anti-resorptive effect of ZOL, and that the primary systemic effect of ZOL on osteoclasts in this model is likely attributed to decreased osteoclast activity, rather than decreased osteoclast numbers. When levels of serum turnover markers were stratified by BRONJ status, ZOL-treated rats with BRONJ had significantly lower P1NP and significantly higher TRAcP 5b compared to ZOL-treated rats without BRONJ. These findings indicate that BRONJ was associated with significantly suppressed systemic bone formation and high numbers of osteoclasts. Together, these findings have important implications in clinical studies that attempt to reduce the cumulative dose of pARs in oncology patients to reduce the incidence of MRONJ (Amadori et al., 2013; Corso et al., 2007; Himelstein et al., 2017; Hortobagyi et al., 2017) . Taken together, these findings support the idea that the unique anatomical and physiological features of alveolar bone play an important role in the specificity of osteonecrosis to the jaws.
The design of this study limits the interpretation of our findings in a few important ways. First, ZOL injections began in normal, periodontally healthy rice rats. Two injections occurred at ages 4 and 8 weeks, when the skeleton is considered juvenile. Since MRONJ is an adverse event that occurs in humans first exposed to pARs in adulthood, future rice rat studies should begin administration of MRONJ-inducing medications after the skeleton has matured (after age 12 weeks) to improve the parallel with the human condition. Second, human MRONJ also occurs in the setting of cancer or osteoporosis where patients, unlike rice rats, not only have a primary disease, but also receive other types of medications. These underlying health issues, or drug treatments, particularly in cancer patients, may elevate the risk of MRONJ. For example, corticosteroids, which negatively influence healing (Rubin & Palestine, 1989; Zitelli, 1987) , are frequently used in treatment protocols for patients with cancer or autoimmune/inflammatory diseases that cause secondary osteoporosis (e.g., rheumatoid arthritis), and may suppress healing of oral wounds. This could account for the observation that humans exposed to oncology doses of ZOL have a roughly 200-fold higher prevalence of MRONJ than osteoporosis patients (Coleman, Marshall et al., 2011; Coleman, Woodward et al., 2011; Grbic et al., 2010; Rathbone et al., 2013; Ruggiero et al., 2014) , which is much higher compared to rice rat data, where oncology doses produced only 2-to 10-fold higher BRONJ prevalence compared to the OP dose after 30 weeks. Third, this study is limited by our inability to fully examine PD and BRONJ in live animals. Thirty-six per cent of BRONJ cases were found in rice rats with no gross oral cavity lesions (GQG < 1), but were symptomatic in the sense that the rats experienced loss of body weight. Diagnostic criteria available in the clinical setting (e.g., periodontal probing, patient-reported pain, dental radiography, cone beam CT) cannot be achieved in a rodent study, so the exact progression of PD and BRONJ, or any spontaneous healing, could not be assessed. Finally, observations of BRONJ in rice rats at necropsy did not allow assessment of the duration of bone exposure. Longitudinal observations and oral examinations in live rice rats in future studies may address some of these limitations.
The reduction in morbidities and mortality, along with the low risk of MRONJ, strongly favours the continued use of pARs in humans.
Therefore, completely describing the aetiology and pathophysiology of MRONJ is more important than ever to patient safety, and could provide evidence that allows development of prevention and treatment strategies for both dental surgery-related and non-surgery-related MRONJ. Additionally, recent case reports describe patients with MRONJ who were not exposed to anti-resorptive or anti-angiogenic medications (Aghaloo & Tetradis, 2017) , suggesting that MRONJ remains an emerging disease that may be associated with yet other medical conditions or drugs.
| CON CLUS ION
This study demonstrates a duration-dependent increase in the prevalence of BRONJ with oncologic ZOL in rice rats with progressive generalized PD. BRONJ prevalence plateaued at a dose only 2.5-fold higher than prevalence with the osteoporosis dose and was consistent with a similar plateau in the anti-resorptive effects of ZOL.
BRONJ and ZOL also produced unique alterations at the tissue level 
